This is not a minor pedagogical point. The entire pharmacovigilance system -- the signal detection chain we traced in Module 1 -- depends on complete capture of adverse events at the site level. And complete capture depends on how coordinators ask questions. Not whether they ask. How.

I have reviewed hundreds of monitoring visit reports over the years, and the pattern is unmistakable: sites that use open-ended, systematic elicitation techniques consistently identify more adverse events than sites that rely on yes/no checklists or leading questions. Not because their participants are sicker. Because their coordinators are more skilled at drawing out what participants actually experienced.

AE elicitation is a clinical skill. It can be taught, practiced, and refined. This lesson teaches the systematic approach.

This is not a minor pedagogical point. The entire pharmacovigilance system -- the signal detection chain we traced in Module 1 -- depends on complete capture of adverse events at the site level. And complete capture depends on how coordinators ask questions. Not whether they ask. How.

I have reviewed hundreds of monitoring visit reports over the years, and the pattern is unmistakable: sites that use open-ended, systematic elicitation techniques consistently identify more adverse events than sites that rely on yes/no checklists or leading questions. Not because their participants are sicker. Because their coordinators are more skilled at drawing out what participants actually experienced.

AE elicitation is a clinical skill. It can be taught, practiced, and refined. This lesson teaches the systematic approach.